ANGLE plc

LSE AGL.L

ANGLE plc Cash and Short-Term Investments for the year ending December 31, 2023: USD 20.63 M

ANGLE plc Cash and Short-Term Investments is USD 20.63 M for the year ending December 31, 2023, a -46.47% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ANGLE plc Cash and Short-Term Investments for the year ending December 31, 2022 was USD 38.55 M, a -10.53% change year over year.
ANGLE plc Cash and Short-Term Investments for the year ending December 31, 2021 was USD 43.09 M, a 10.25% change year over year.
ANGLE plc Cash and Short-Term Investments for the year ending December 31, 2020 was USD 39.08 M, a 685.06% change year over year.
ANGLE plc Cash and Short-Term Investments for the year ending December 31, 2019 was USD 4.98 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

LSE: AGL.L

ANGLE plc

CEO	Mr. Andrew David William Newland ACA, Meng
IPO Date	March 17, 2004
Location	United Kingdom
Headquarters	Surrey Research Park
Employees	150
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Key trends

Past 5 years